Advanced searches left 3/3

Cas9 genome editing - DOAJ

Summarized by Plex Scholar
Last Updated: 26 September 2022

* If you want to update the article please login/register

CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis

In the EVs that were isolated from CRISPR/Cas9-labeled cells isolated from GFP-CD63 over-expressing cells, we can see a larger fraction of single-GFP-labeled EVs isolated from CRISPR/Cas9-modified cells compared to EVs isolated from GFP-CD63 over-expressing cells, according to our report. We fluorescently labeled EVs with the HaloTag u00ae 666, which allowed us to perform 3D-localization microscopy of single EVs cultured by the cultured cells to show the versatility of the CRISPR/Cas9 genome editing technique.

Source link: https://doi.org/10.3390/ijms23010282


FACS-assisted CRISPR-Cas9 genome editing of human induced pluripotent stem cells

Summary: Using CRISPR-Cas9 technology, this paper lays out a cost-effective and reproducible protocol for the generation of genetically modified human induced pluripotent stem cells by genome editing. Using single-cell sorting by flow cytometry, we explore here how we developed knockout and knockin clonal populations of hiPSCs.

Source link: https://doi.org/10.1016/j.xpro.2022.101680


The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

In addition, several researchers used the CRISPR/Cas9 system to cure or cure cancers by various methods, including gene therapy and immune therapy. Aim of Review: We conclude the recent application and clinical trials of CRISPR/Cas9 in non-cancerous diseases and cancers, pointing out some of the difficulties that need to be addressed. CRISPR/Cas9 technologies can be used to diagnose certain gene-related diseases by disrupting, inserting, correcting, replacing, or blocking genes for clinical use with gene therapy, due to its high accuracy and sensitivity.

Source link: https://doi.org/10.1016/j.jare.2021.11.018


CRISPR/Cas9 Genome Editing: Future Treatment of Duane Retraction Syndrome

Limited eye movement is characteristic of Duane Retraction Syndrome. CRISPR/Cas9, a tool for gene editing with a variety of applications, including genetic disorders, should be considered for the treatment. Using the CCTop website, we created sgRNA as the first step in using CRISPR/Cas9 as a treatment for DRS in silico. CRISPR/Cas9 can repair genetic mutations by computing sgRNA, performing experiments, and reporting the findings. There are no articles on the use of CRISPR/Cas9 in DRS at this time. Hence, this report could be highly useful as a starting point for treating CRISPR/Cas9 as a DRS therapy.

Source link: https://doi.org/https://doi.org/10.7454/psr.v9i1.1231


Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing

CRISPR-Cas9 technology has revolutionized genome editing and has demonstrated remarkable promise in treating otherwise incurable diseases. Engineering activities to facilitate quick intracellular delivery of CRISPR-Cas9 components has been a primary aim in broadening the reach of the CRISPR-Cas9 technology. Given their safe performance profiles over viral devices, several non-viral delivery systems for CRISPR-Cas9 have been investigated.

Source link: https://doi.org/10.1186/s12951-022-01570-y

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions